X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare TTK HEALTHCARE with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TTK HEALTHCARE vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TTK HEALTHCARE PANACEA BIOTECH TTK HEALTHCARE/
PANACEA BIOTECH
 
P/E (TTM) x 18.3 -16.7 - View Chart
P/BV x 6.0 2.0 300.8% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 TTK HEALTHCARE   PANACEA BIOTECH
EQUITY SHARE DATA
    TTK HEALTHCARE
Mar-14
PANACEA BIOTECH
Mar-14
TTK HEALTHCARE/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs663149 446.1%   
Low Rs39982 484.8%   
Sales per share (Unadj.) Rs535.684.1 636.6%  
Earnings per share (Unadj.) Rs15.9-18.3 -87.1%  
Cash flow per share (Unadj.) Rs20.0-6.7 -298.9%  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs137.683.7 164.4%  
Shares outstanding (eoy) m7.7761.25 12.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.01.4 72.2%   
Avg P/E ratio x33.3-6.3 -528.0%  
P/CF ratio (eoy) x26.5-17.2 -153.8%  
Price / Book Value ratio x3.91.4 279.8%  
Dividend payout %25.10-   
Avg Mkt Cap Rs m4,1277,074 58.3%   
No. of employees `0001.72.8 62.1%   
Total wages/salary Rs m6071,449 41.9%   
Avg. sales/employee Rs Th2,436.71,874.1 130.0%   
Avg. wages/employee Rs Th355.2527.0 67.4%   
Avg. net profit/employee Rs Th72.5-407.7 -17.8%   
INCOME DATA
Net Sales Rs m4,1625,154 80.8%  
Other income Rs m61100 61.3%   
Total revenues Rs m4,2235,254 80.4%   
Gross profit Rs m197-766 -25.7%  
Depreciation Rs m32711 4.5%   
Interest Rs m301,503 2.0%   
Profit before tax Rs m197-2,881 -6.8%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m7317 433.3%   
Profit after tax Rs m124-1,121 -11.0%  
Gross profit margin %4.7-14.9 -31.9%  
Effective tax rate %37.0-0.6 -6,345.8%   
Net profit margin %3.0-21.8 -13.7%  
BALANCE SHEET DATA
Current assets Rs m1,6293,810 42.7%   
Current liabilities Rs m1,0588,365 12.6%   
Net working cap to sales %13.7-88.4 -15.5%  
Current ratio x1.50.5 338.0%  
Inventory Days Days30156 19.1%  
Debtors Days Days3467 50.0%  
Net fixed assets Rs m55614,480 3.8%   
Share capital Rs m7861 126.8%   
"Free" reserves Rs m878903 97.3%   
Net worth Rs m1,0695,127 20.9%   
Long term debt Rs m1595,832 2.7%   
Total assets Rs m2,39919,433 12.3%  
Interest coverage x7.6-0.9 -826.9%   
Debt to equity ratio x0.11.1 13.0%  
Sales to assets ratio x1.70.3 654.0%   
Return on assets %6.42.0 326.3%  
Return on equity %11.6-21.9 -53.0%  
Return on capital %18.53.6 507.5%  
Exports to sales %0.824.5 3.2%   
Imports to sales %1.410.2 13.8%   
Exports (fob) Rs m331,264 2.6%   
Imports (cif) Rs m58525 11.1%   
Fx inflow Rs m331,539 2.1%   
Fx outflow Rs m63942 6.7%   
Net fx Rs m-30597 -5.1%   
CASH FLOW
From Operations Rs m127599 21.1%  
From Investments Rs m-146-438 33.3%  
From Financial Activity Rs m22-303 -7.2%  
Net Cashflow Rs m3-141 -1.8%  

Share Holding

Indian Promoters % 65.4 74.5 87.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 0.6 616.7%  
FIIs % 5.2 1.3 400.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.8 23.6 109.3%  
Shareholders   12,723 10,259 124.0%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TTK HEALTHCARE With:   NOVARTIS  ASTRAZENECA PHARMA  DISHMAN PHARMA  IPCA LABS  JUBILANT LIFE SCIENCES  

Compare TTK HEALTHCARE With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 331 Points Higher; Oil & Gas Stocks Witness Buying(Closing)

After opening on a negative note, share markets in India witnessed buying interest during closing hours and ended the day on a positive note.

Related Views on News

TTK HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 15.3% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, TTK HEALTHCARE has posted a net profit of Rs 67 m (down 15.3% YoY). Sales on the other hand came in at Rs 2 bn (up 16.3% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

TTK HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Down 276.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, TTK HEALTHCARE has posted a net profit of Rs 79 m (down 276.0% YoY). Sales on the other hand came in at Rs 2 bn (up 38.1% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

3 Big Money Makers to Round Out Your 2018 Portfolio(Profit Hunter)

Oct 31, 2018

The market is offering many strong opportunities in the small cap space right now. Don't miss out. This is the time to get rich.

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TTK HEALTHCARE SHARE PRICE


Nov 13, 2018 (Close)

TRACK TTK HEALTHCARE

  • Track your investment in TTK HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TTK HEALTHCARE

TTK HEALTHCARE - CIPLA COMPARISON

COMPARE TTK HEALTHCARE WITH

MARKET STATS